A photo of Kevin Doyle, Vice President of Medicinal Chemistry and DMPK

Kevin Doyle

Vice President of Medicinal Chemistry & DMPK

Kevin is an experienced drug hunter, with over 20 years in the industry encompassing biotech, pharma and CROs.  He has led successful teams and driven major strategic collaborations, in a variety of different therapeutic areas.  These collaborations have been all along the drug discovery gamut, from hit finding activities to lead optimisation programmes that have successfully delivered compounds into pre-clinical and clinical settings. 

Prior to joining CRH, he led the medicinal chemistry efforts at Cerevance, a biotech based in Cambridge focussing on novel targets for neurodegeneration.  Kevin is the co-author/co-inventor on over 40 scientific papers and patents.